Abstract 2092: The ALK inhibitor NMS-E628 also potently inhibits ROS1 and induces tumor regression in ROS-driven models .
Elena Ardini(Nerviano Medical Sciences), Arturo Galvani(Nerviano Medical Sciences), Maria Laura Giorgini(Nerviano Medical Sciences), Paolo Orsini(Nerviano Medical Sciences), Nilla Avanzi(Nerviano Medical Sciences), Maria Menichincheri(Nerviano Medical Sciences), Nadia Amboldi(University of Pavia), Daniele Casero(Nerviano Medical Sciences), Maria Beatrice Saccardo(Nerviano Medical Sciences), Enrico Pesenti, Patrizia Banfi(Nerviano Medical Sciences), Antonella Isacchi(Nerviano Medical Sciences)
Cited by 10
Related Papers
Discovery of drug mode of action and drug repositioning from transcriptional responses
|Proceedings of the National Academy of Sciences|2010|853
Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
|Molecular Cancer Therapeutics|2016|317
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.
|Proceedings of the National Academy of Sciences|1995|205
The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
|Molecular Oncology|2014|156
Divergent effects of RIP1 or RIP3 blockade in murine models of acute liver injury
|Cell Death and Disease|2015|129